文献速递肝病

测量γ-谷氨酰转移酶以确定原发性胆汁性胆管炎患者肝移植或死亡风险

Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-08-07

基于全球PBC研究组14个中心2129例患者数据,分析血清GGT与肝移植或肝相关死亡的关联。治疗12个月后GGT超过正常上限3.2倍可识别10年内需肝移植或肝相关死亡的患者,AUC为0.70。即使ALP低于正常上限1.5倍,GGT高于3.2倍ULN者风险仍高于GGT低于3.2倍ULN且ALP低于1.5倍ULN者(P<.05)。

要点

  • 治疗12个月后GGT>3.2倍ULN可识别10年内肝移植或肝相关死亡风险,AUC为0.70。
  • ALP<1.5倍ULN但GGT>3.2倍ULN者,肝移植或肝相关死亡风险高于GGT<3.2倍ULN且ALP<1.5倍ULN者(P<.05)。
  • GGT信息可提高Globe评分的预后价值。

核心结论

  • 血清GGT水平可用于识别PBC患者肝移植或死亡风险,并提高ALP测量的预后价值。
  • 作者认为研究结果支持将GGT作为临床试验的主要临床终点。
  • 作者认为在ALP水平低的患者中,高GGT水平可识别可能需要代谢紊乱治疗或PBC治疗升级的患者。

研究设计与样本

  • 分析全球PBC研究组数据,该组包括欧洲和北美14个中心。
  • 纳入2129例PBC患者,281例(13%)达到肝相关临床终点。
  • 诊断时平均年龄53岁,91%为女性。
  • 获取基线和治疗后时间点的血清GGT测量值,使用Cox模型风险比评估GGT与临床结局的关联。

主要发现

  • 血清GGT与ALP相关(r=0.71)。
  • 基于基线和每年至多5年收集的数据,较高的血清GGT水平与较低的无移植生存风险相关。
  • 治疗12个月后GGT高于正常上限3.2倍可识别10年内需肝移植或肝相关死亡的患者,AUC为0.70。
  • GGT高于3.2倍ULN但ALP低于1.5倍ULN者,肝移植或肝相关死亡风险高于GGT低于3.2倍ULN且ALP低于1.5倍ULN者(P<.05)。
  • 纳入GGT信息提高了Globe评分的预后价值。

临床怎么用

  • 作者认为血清GGT水平可用于识别PBC患者肝移植或死亡风险,并提高ALP测量的预后价值。
  • 作者认为研究结果支持将GGT作为临床试验的主要临床终点。
  • 作者认为在ALP水平低的患者中,高GGT水平可识别可能需要代谢紊乱治疗或PBC治疗升级的患者。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Gamma-glutamyltransferase (GGT) is a serum marker of cholestasis. We investigated whether serum level of GGT is a prognostic marker for patients with primary biliary cholangitis (PBC). METHODS: We analyzed data from patients with PBC from the Global PBC Study Group, comprising 14 centers in Europe and North America. We obtained measurements of serum GGT at baseline and time points after treatment. We used Cox model hazard ratios to evaluate the association between GGT and clinical outcomes, including liver transplantation and liver-related death. RESULTS: Of the 2129 patients included in our analysis, 281 (13%) had a liver-related clinical endpoint. Mean age at diagnosis was 53 years and 91% of patients were female patients. We found a correlation between serum levels of GGT and alkaline phosphatase (ALP) (r = 0.71). Based on data collected at baseline and yearly for up to 5 years, higher serum levels of GGT were associated with lower hazard for transplant-free survival. Serum level of GGT at 12 months after treatment higher than 3.2-fold the upper limit of normal (ULN) identified patients who required liver transplantation or with liver-related death at 10 years with an area under the receiver operating characteristic curve of 0.70. The risk of liver transplantation or liver-related death in patients with serum level of GGT above 3.2-fold the ULN, despite level of ALP lower than 1.5-fold the ULN, was higher compared to patients with level of GGT lower than 3.2-fold the ULN and level of ALP lower than 1.5-fold the ULN (P < .05). Including information on level of GGT increased the prognostic value of the Globe score. CONCLUSIONS: Serum level of GGT can be used to identify patients with PBC at risk for liver transplantation or death, and increase the prognostic value of ALP measurement. Our findings support the use of GGT as primary clinical endpoint in clinical trials. In patients with low serum level of ALP, a high level of GGT identifies those who might require treatment of metabolic disorders or PBC treatment escalation.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Gerussi A, Bernasconi DP, O'Donnell SE, et al. Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis. Clin Gastroenterol Hepatol. 2020. PMID: 32777554. doi:10.1016/j.cgh.2020.08.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。